

Secondary Logo



Journal Logo

Articles



Advanced Search

November 2011 - Volume 21 - Issue 11

- Previous Abstract
- Next Abstract

- **Cite**



- Copy

- Export to RIS

- Export to EndNote

- **Share**

- Email

- Facebook

- Twitter

- LinkedIn

- **Favorites**

- **Permissions**

- **More**

- Cite

- Permissions

ORIGINAL ARTICLES

Ramipril modulates circadian gene expression in skeletal muscle

Sauermann, Robert^a; Schmidt, Wolfgang M.^b; Krebs, Michael^c; Brunner, Martin^a; Müller, Markus^a

Author Information

^aDepartment of Clinical Pharmacology

^bCenter of Anatomy and Cell Biology, Neuromuscular Research Department,

^cDivision of Endocrinology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Correspondence to Martin Brunner, MD, Währinger Gürtel 18-20, 1090 Vienna, Austria Tel: +43 1 40400 2981; fax: +43 1 40400 2998; e-mail: martin.brunner@meduniwien.ac.at

Received September 9, 2010

Accepted July 4, 2011

Pharmacogenetics and Genomics: November 2011 - Volume 21 - Issue 11 - p 751-759

doi: 10.1097/FPC.obo13e32834a8621

- Buy

Metrics

Abstract

Objectives

Treatment with angiotensin converting enzyme (ACE)-inhibitors favorably affects glucose metabolism and the development of diabetes mellitus by largely elusive mechanisms. To identify these mechanisms, we studied the effect of ACE-inhibition on gene expression in skeletal muscle, a primary target tissue for insulin in glucose homeostasis.

Methods

A subject-blinded and analyst-blinded, placebo-controlled study was conducted in nine healthy men. Two consecutive muscle biopsies were conducted before and 9 h after a single dose of either 10-mg ramipril ($n=6$) or placebo ($n=3$), (randomly allocated). Muscle ribonucleic acid was subjected to transcriptome profiling.

Results


In both ramipril-treated or placebo-treated individuals, the majority of genes with differential expression between the two time points belonged to the family of diurnally regulated genes, such as the *NR1D1* and *NR1D2* genes (nuclear receptor subfamily 1, group D, members 1 and 2) or members of the period homolog family (*PER1-3*). Ramipril significantly modulated the expression of other diurnally regulated genes, such as aryl hydrocarbon receptor nuclear translocator-like (*ARNTL*), encoding aryl hydrocarbon receptor nuclear translocator-like, a core component of the circadian clock ($P=0.02$). Concomitant attenuation of *NR1D1* downregulation (-2.4 -fold compared with -4.1 -fold in placebo; $P=0.04$), a transcriptional repressor of *ARNTL*, supported the view that ramipril might modulate glucose homeostasis pathways involving the *NR1D1* *ARNTL* axis.

Conclusion

As circadian rhythms are deranged in patients who are diabetic, modulated expression of circadian clock genes by ramipril could explain the favorable metabolic effects of therapeutic ACE-inhibition.

© 2011 Lippincott Williams & Wilkins, Inc.

^Back to Top



Never Miss an Issue

Get new journal Tables of Contents sent right to your email inbox

Type your email

Get New Issue Alerts

Browse Journal Content

- Most Popular
- For Authors
- About the Journal
- Past Issues
- Current Issue
- Register on the website
- Subscribe
- Get eTOC Alerts

For Journal Authors

- Submit an article
- How to publish with us

Customer Service

- Activate your journal subscription
- Activate Journal Subscription
- Browse the help center
- Help
- Contact us at:
 - EMAIL:
customerservice@lww.com
 - TEL: (USA):
TEL: (Int'l):
800-638-3030 (within USA)
301-223-2300 (international)
- 
- Privacy Policy (Updated June 1, 2020)
- Legal Disclaimer
- Terms of Use
- Open Access Policy
- Sitemap
- RSS Feeds
- LWW Journals
- Copyright © 2021
- Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved.